Rolling up our sleeves now to reap the benefits later: Preparing the community for an adolescent HIV vaccine

Current Opinion in HIV and AIDS

Volumn 2, Issue 5, 2007, Pages 375-384

  Kapogiannis, Bill G ^a   Lee, Sonia S ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Adolescent HIV vaccine; Community preparedness

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MICROBICIDE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ATTITUDE; CAREGIVER; COMMUNITY; CONFIDENTIALITY; DECISION MAKING; EDUCATION; ETHICS; EXPECTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION PREVENTION; INFORMED CONSENT; INTERVENTION STUDY; JUVENILE; MONITORING; PRIMARY PREVENTION; PRIORITY JOURNAL; RESEARCH; REVIEW; SCIENTIST; SEX; UNITED STATES; VULNERABLE POPULATION; WORK;

EID: 34547891930     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3282cecf0a     Document Type: Review

References (57)

1. Joint United Nations Program on AIDS. Preventing HIV/AIDS in young people: a systematic review of the evidence from developing countries. Geneva, Switzerland: World Health Organization; 2006.
2. Singh JA, Karim SS, Karim QA, et al. Enrolling adolescents in research on HIV and other sensitive issues: lessons from South Africa. PLoS Med 2006; 3:e180.
3. US Centers for Disease Control and Prevention. HIV/AIDS among youth. Atlanta, Georgia: US Centers for Disease Control and Prevention; 2006. http://www.cdc.gov/hiv/resources/factsheets/youth.htm [Accessed 19 June 2007].
4. Rangel MC, Gavin L, Reed C, et al. Epidemiology of HIV and AIDS among adolescents and young adults in the United States. J Adolesc Health 2006; 39:156-163.
5. Wasserman J, Flannery MA, Clair JM. Raising the ivory tower: the production of knowledge and distrust of medicine among African Americans. J Med Ethics 2007; 33:177-180.
6. Olansky S, Simpson L, Schuman SH. Environmental factors in the Tuskegee study of untreated syphilis. Public Health Rep 1954; 69:691-698.
7. Underwood C, Hachonda H, Serlemitsos E, Bharath-Kumar U. Reducing the risk of HIV transmission among adolescents in Zambia: psychosocial and behavioral correlates of viewing a risk-reduction media campaign. J Adolesc Health 2006; 38:55.
8. Family Health International. YouthNet. End of program report - taking action: recommendations and resources. Arlington, Virginia: Family Health International; 2006. http://www.fhi.org/NR/rdonlyres/exn6sh7ohl6ap2ojsmydmflqd- dmsy6egme7k4owidsfxdyob64lrnxf4ollkmhyiwbpplw73jdjkro/EOPreport.pdf [Accessed 19 June 2007].
9. Kirby DB, Laris BA, Rolleri LA. Sex and HIV education programs: their impact on sexual behaviors of young people throughout the world. J Adolesc Health 2007; 40:206-217.
10. Pande R, Kurz K, Walia S, et al. Improving the Reproductive Health of Married and Unmarried Youth in India. Washington, District of Columbia: International Center for Research on Women; 2006.
11. Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007; 369:657-666.
12. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007; 369:643-656.
13. Liu AY, Grant RM, Buchbinder SP. Preexposure prophylaxis for HIV: unproven promise and potential pitfalls. JAMA 2006; 296:863-865.
14. US Centers for Disease Control and Prevention. CDC trials of pre-exposure prophylaxis for HIV prevention: clinical trials in Botswana, Thailand, and the United States. Atlanta, Georgia: US Centers for Disease Control and Prevention; 2006. http://aidsvaccineclearinghouse.org/pdf/trials_activity/ CDC_TenofovirFactSheet_August_06.pdf [Accessed 19 June 2007].
15. Kilmarx PH, van de Wijgert JH, Chaikummao S, et al. Safety and acceptability of the candidate microbicide Carraguard in Thai Women: findings from a phase II clinical trial. J Acquir Immune Defic Syndr 2006; 43:327-334.
16. Microbicide Trials Network. MTN studies. Pittsburgh, Pennsylvania: Microbicide Trials Network; 2007. http://www.mtnstopshiv.org/?q=node/132 [Accessed 19 June 2007].
17. Ostrow DG, Silverberg MJ, Cook RL, Chmiel JS, Johnson L, Li X, et al. Prospective Study of Attitudinal and Relationship Predictors of Sexual Risk in the Multicenter AIDS Cohort Study. AIDS Behav 2007 [Epub ahead of print].
18. Marrazzo J. Syphilis and other sexually transmitted diseases in HIV infection. Top HIV Med 2007; 15:11-16.
19. Olin J, Kokolamami J, Lepira FB, et al. Community preparedness for HIV vaccine trials in the Democratic Republic of Congo. Cult Health Sex 2006; 8:529-544.
20. Brooks RA, Newman PA, Duan N, Ortiz DJ. HIV vaccine trial preparedness among Spanish-speaking Latinos in the US. AIDS Care 2007; 19:52-58.
21. Patton GC, Viner R. Pubertal transitions in health. Lancet 2007; 369:1130-1139.
22. Petersen A. Developmental Issues in Adolescent Health. In: Coates T, Petersen A, Perry C, editors. Promoting adolescent health: a dialog on research and practice. New York City, New York: Academic Press; 1982 . pp. 61-71.
23. Koblin BA, Holte S, Lenderking B, Heagerty P. Readiness for HIV vaccine trials: changes in willingness and knowledge among high-risk populations in the HIV network for prevention trials. The HIVNET Vaccine Preparedness Study Protocol Team. J Acquir Immune Defic Syndr 2000; 24:451-457.
24. Brown-Peterside P, Chiasson MA, Ren L, Koblin BA. Involving women in HIV vaccine efficacy trials: lessons learned from a vaccine preparedness study in New York City. J Urban Health 2000; 77:425-437.
25. Jaspan HB, Berwick JR, Myer L, et al. Adolescent HIV prevalence, sexual risk, and willingness to participate in HIV vaccine trials. J Adolesc Health 2006; 39:642-648.
26. Murphy DA, Hoffman D, Seage GR 3rd, et al. Improving comprehension for HIV vaccine trial information among adolescents at risk of HIV. AIDS Care 2007; 19:42-51.
27. Koblin BA, Heagerty P, Sheon A, et al. Readiness of high-risk populations in the HIV Network for Prevention Trials to participate in HIV vaccine efficacy trials in the United States. AIDS 1998; 12:785-793.
28. Buchbinder SP, Metch B, Holte SE, et al. Determinants of enrollment in a preventive HIV vaccine trial: hypothetical versus actual willingness and barriers to participation. J Acquir Immune Defic Syndr 2004; 36:604-612.
29. Halpern SD, Metzger DS, Berlin JA, Ubel PA. Who will enroll? Predicting participation in a phase II AIDS vaccine trial. J Acquir Immune Defic Syndr 2001; 27:281-288.
30. O'Connell JM, Hogg RS, Chan K, et al. Willingness to participate and enroll in a phase 3 preventive HIV-1 vaccine trial. J Acquir Immune Defic Syndr 2002; 31:521-528.
31. Smith-Rogers A. Report on NIH-community consultation on including adolescents in HIV prevention vaccine research. Bethesda, Maryland: US National Institutes of Health; 2001.
32. Mills E, Cooper C, Guyatt G, et al. Barriers to participating in an HIV vaccine trial: a systematic review. AIDS 2004; 18:2235-2242.
33. Liau A, Zimet GD. The acceptability of HIV immunization: examining vaccine characteristics as determining factors. AIDS Care 2001; 13:643-650.
34. Mays RM, Zimet GD. Recommending STI vaccination to parents of adolescents: the attitudes of nurse practitioners. Sex Transm Dis 2004; 31:428-432.
35. Swartz L, Kagee A, Kafaar Z, et al. Social and behavioral aspects of child and adolescent participation in HIV vaccine trials. J Int Assoc Physicians AIDS Care (Chic Ill) 2005; 4:89-92.
36. Slack C, Kruger M. The South African Medical Research Council's Guidelines on Ethics for Medical Research: implications for HIV-preventive vaccine trials with children. S Afr Med J 2005; 95:269-271.
37. Slack C, Strode A, Grant C, Milford C. Implications of the ethical-legal framework for adolescent HIV vaccine trials: report of a consultative forum. S Afr Med J 2005; 95:682-684.
38. US Food and Drug Administration. Guidance for industry: development of preventive HIV vaccines for use in pediatric populations. Rockville, Maryland: US Food and Drug Administration; 2006. http://www.fda.gov/cber/gdlns/pedhiv.pdf [Accessed 20 June 2007].
39. US Food and Drug Administration. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine label. Rockville, Maryland: US Food and Drug Administration; 2006. http://www.fda.gov/cber/label/hpvmer060806LB.pdf [Accessed 20 June 2007].
40. Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006; 118:2135-2145.
41. AIDS Vaccine Advocacy Coalition. Adolescents: the missing cohort. New York City, New York: AIDS Vaccine Advocacy Coalition; 2006. http://www.avac.org/ adolescent_missing_cohort.pdf [Accessed 20 June 2007].
42. US Centers for Disease Control and Prevention. Acute hepatitis B among children and adolescents: United States, 1990-2002. MMWR Morb Mortal Wkly Rep 2004, 53:1015-1018. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5343a4.htm [Accessed 20 June 2007].
43. Jaspan HB, Gray GE, Robinson AK, et al. Scientific justification for the participation of children and adolescents in HIV-1 vaccine trials in South Africa. S Afr Med J 2005; 95:685-687.
44. South African AIDS Vaccine Initiative. First large-scale study of HIV vaccine starts in South Africa: Phambili trial seeks 3000 participants. Cape Town: South Africa; 2007. http://www.saavi.org.za/1press2007.htm [Accessed 20 June 2007].
45. HIV Vaccines Trial Network. Community. Seattle, Washington: HIV Vaccines Trial Network; 2007. http://www.hvtn.org/community/index.html [Accessed 20 June 2007].
46. AIDS Vaccine Advocacy Coalition. About AIDS vaccines. New York City, New York: AIDS Vaccine Advocacy Coalition; 2006. http://www.avac.org/vaccines.htm [Accessed 20 June 2007].
47. AIDS Vaccine Advocacy Coalition. AIDS vaccines: the next frontiers. New York City, New York: AIDS Vaccine Advocacy Coalition; 2006. http://www.avac.org/ pdf/reports/2006_Report/AVAC_Report_2006_single.pdf [Accessed 20 June 2007].
48. US National Institute of Allergy and Infectious Diseases. Be the generation. Bethesda, Maryland: US National Institute of Allergy and Infectious Diseases; 2001. http://www.bethegeneration.org/index.cfm [Accessed 20 June 2007].
49. Ziff MA, Harper GW, Chutuape KS, et al. Laying the foundation for Connect to Protect: a multisite community mobilization intervention to reduce HIV/AIDS incidence and prevalence among urban youth. J Urban Health 2006; 83:506-522.
50. Katz MH, Schwarcz SK, Kellogg TA, et al. Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco. Am J Public Health 2002; 92:388-394.
51. Dukers NH, Goudsmit J, de Wit JB, et al. Sexual risk behaviour relates to the virological and immunological improvements during highly active antiretroviral therapy in HIV-1 infection. AIDS 2001; 15:369-378.
52. Agot KE, Kiarie JN, Nguyen HQ, et al. Male circumcision in Siaya and Bondo Districts, Kenya: prospective cohort study to assess behavioral disinhibition following circumcision. J Acquir Immune Defic Syndr 2007; 44:66-70.
53. Nelson K. Thai HIV vaccine trial prompts angry exchanges. Lancet 2004; 363:299.
54. Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006; 194:1661-1671.
55. Flynn NM, Forthal DN, Harro CD, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191:654-665.
56. Johnston MI, Fauci AS. An HIV vaccine: evolving concepts. N Engl J Med 2007; 356:2073-2081.
57. Lindegger G, Milford C, Slack C, et al. Beyond the checklist: assessing understanding for HIV vaccine trial participation in South Africa. J Acquir Immune Defic Syndr 2006; 43:560-566.